Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
ArcticLine Feasibility Study
NCT03604263 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the ArcticLine Feasibility Study is to collect preliminary safety and effectiveness data on the ArcticLine Catheter.
Conditions Studied
Interventions
- DEVICE ArcticLine Cardiac Cryoablation Catheter
Study Locations (4)
Florida
- BayCare Medical Group Cardiology — Tampa
Michigan
- University of Michigan — Ann Arbor
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) — Pittsburgh
Quebec
- Montreal Heart Institute — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-10-18 |
| Est. Completion | 2019-11-18 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604263
The ClinicalTrials.gov registry entry for NCT03604263 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which ArcticLine Cardiac Cryoablation Catheter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03604263 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Florida, Michigan, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03604263 about?
NCT03604263 is a clinical study titled "ArcticLine Feasibility Study". The purpose of the ArcticLine Feasibility Study is to collect preliminary safety and effectiveness data on the ArcticLine Catheter.
What is the current status of trial NCT03604263?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2018-10-18. Estimated completion is 2019-11-18.
What conditions does trial NCT03604263 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03604263?
The interventions under investigation include: ArcticLine Cardiac Cryoablation Catheter (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03604263?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03604263 being conducted?
This trial has 4 study locations across Florida, Michigan, Pennsylvania, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.